If you have been reading about REV-ERB agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
== Discovery == The discovery of hepatalin action was published in 1996 by a team led by W. Wayne Lautt from the University of Manitoba in Winnipeg, Manitoba, Canada. The many roles of the hepatic nerves had been studied for years with Lautt proposing in 1979 that hepatic parasympathetic nerve dysfunction could result in type 2 diabetes. The action of hepatalin was not seen until 1991 when an experiment was conducted to determine if insulin in the blood perfusing the brain could activate the nerves in the liver. It did not, but the response to an injection of a pulse of insulin either to the brain or systemically, was decreased by hepatic surgical denervation. Further studies showed that denervation of the liver reduced the response to insulin in the hindlimbs but had no effect on the liver.
==== Triglyceride ==== In this process, green coffee beans are soaked in a hot water and coffee solution to draw the caffeine to the surface of the beans. Next, the beans are transferred to another container and immersed in coffee oils that were obtained from spent coffee grounds and left to soak. After several hours of high temperatures, the triglycerides in the oils remove the caffeine, but not the flavor elements, from the beans. The beans are separated from the oils and dried. The caffeine is removed from the oils, which are reused to decaffeinate another batch of beans. This is a direct-contact method of decaffeination.
Todd Lynn Helton (born August 20, 1973) is an American former professional baseball first baseman who played his entire 17-year Major League Baseball (MLB) career for the Colorado Rockies. A five-time All-Star, four-time Silver Slugger, and three-time Gold Glove Award winner, Helton holds the Rockies' club records for hits (2,519), home runs (369), doubles (592), walks (1,335), runs scored (1,401), runs batted in (RBIs, with 1,406), games played (2,247), and total bases (4,292), among others. Helton grew up in Tennessee and played college baseball and football for the Tennessee Volunteers. The Rockies drafted him in the first round of the 1995 MLB draft, and he debuted in the majors in 1997. During his peak from 1999 to 2004, Helton met or topped these benchmarks each season: .320 batting average, 39 doubles, 30 home runs, 107 runs scored, 96 RBI, .577 slugging percentage and .981 on-base plus slugging. In 2000, he won the batting title with a .372 average and also led MLB with a .698 slugging percentage, 59 doubles, and 147 RBI and the National League (NL) with 216 hits. Helton helped the Rockies win the NL pennant in 2007 before being swept in the World Series. He collected his 2,000th career hit in May 19, 2009 and his 2,500th on September 1, 2013. He retired at the end of that season, homering in his final game at Coors Field. Helton was inducted into the Baseball Hall of Fame in 2024, his sixth year on the ballot.
He claimed that Mubadala attempted to take over all shares of the founders, and “intentionally delayed” transferring units to them. Getir's founders also stated that Mubadala attempted to back off from the deal at the end of 2024. They appealed to the Enterprise Chamber of the Amsterdam Court of Appeal, and said to take a legal action in Turkey and the UK as well. Mubadala was planning to propose an alternative plan, which it said was already approved by Getir's independent directors. But Salur expressed his intent to “continue fighting” the restructuring plan. On 30 January 2025, Salur removed Getir's CEO Batuhan Gultakan from his position without giving specific reasons. Sources revealed that the move was taken due to Gultakan's full support towards Mubadala. In December 2024, Mubadala announced a partnership with Silver Rock Financial LP in which Mubadala Capital acquired a 42% stake in the company. Mubadala Capital acquired the Canadian asset manager CI Financial Corp. in August 2025 for $8.9 billion. Also in August 2025, Mubadala invested $35 million for a 12.8% stake into Paragraf, a British technology company. Mubadala Capital acquired the outdoor advertising company Clear Channel Outdoor in February 2026 for $6.2 billion.
The most northerly black smokers are a cluster of five named Loki's Castle, discovered in 2008 by scientists from the University of Bergen at 73°N, on the Mid-Atlantic Ridge between Greenland and Norway. These black smokers are of interest as they are in a more stable area of the Earth's crust, where tectonic forces are less and consequently fields of hydrothermal vents are less common. The world's deepest known black smokers are located in the Cayman Trough, 5,000 m (3.1 miles) below the ocean's surface.
Sources: en.wikipedia.org
=== Phase 2a clinical trial – ABSSSI === Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus aureus Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus aureus The study started in October 2010 and had a primary completion date of December 2011 for final data collection for the primary outcome measure. Overall, 215 patients were randomized into either one of the three brilacidin arms or the active comparator Daptomycin arm. There were three dosing regimens for brilacidin, a low, medium and high dose administered for three days, and one dosing regimen for Daptomycin administered for seven days. The clinical trial was successful, demonstrating safety and clinical efficacy for all evaluated doses of brilacidin, with three-day brilacidin cure rates of all dosing regimens comparable with seven days of Daptomycin. The results indicated the potential for a shorter brilacidin dosing regimen. Shorter dosing regimens are important as they reduce the risks from Intravenous therapy complications, reduce costs such as reduced hospital stays and clinic visits, and can help reduce the emergence of antibiotic resistance through a combination of a quick bacterial kill, shorter duration of treatment, and increased patient compliance.
== Reaction and metabolism == The overall reaction catalyzed by MTHFR is illustrated on the right. The reaction uses an NAD(P)H hydride donor and an FAD cofactor. The E. coli enzyme has a strong preference for the NADH donor, whereas the mammalian enzyme is specific to NADPH.
viticella) and its cultivars). Montana Group: Cultivars belonging to, or derived from, species classified in section Montanae (Schneider) Grey-Wilson such as C. chrysocoma, C. montana, C. spooneri. Tangutica Group: Cultivars with at least one parent belonging to, or derived from, species classified in section Meclatis (Spach) Baill., such as C. intricata, C. ladakhiana, C. orientalis, C. serratifolia, C. tangutica, C. tibetana. This Group has also been known as the Orientalis Group. Texensis Group: Cultivars derived from C. texensis crossed with representatives from either of the Large-flowered Groups. Viorna Group: Cultivars with at least one parent belonging to, or derived from, species classified in section Viorna A. Gray, such as C. crispa, C. fusca, C. ianthina, C. pitcheri, C. reticulata, C. texensis, C. viorna. Cultivars assigned to Texensis Group, and cultivars with C. integrifolia in their parentage, are excluded. Vitalba Group: Cultivars with at least one parent belonging to, or derived from, species classified in section Clematis L., such as C. ligusticifolia, C. potaninii, C. vitalba, C. virginiana. Viticella Group: Cultivars with at least one parent mainly derived from C. viticella. Excludes hybrids between C. integrifolia and C. viticella: see Integrifolia Group. Large-flowered Division: Flowers (5–)10–22(–29) cm across, usually flat. Early Large-flowered Group: Comprises the former Patens Group and Fortunei Group. Cultivars of the Patens Group were derived mainly from C. patens, either directly or indirectly.
. The preferred decay channel of those theories is p → e+ + π0. GUT theories find strong support in the convergence of the three Standard Model running coupling constants. These correspond to the fundamental interactions: α1 for the electromagnetic (hypercharge) interaction, α2 for the weak interaction, and α3 for the strong interaction. They follow renormalization group equations: α3 increases at low energies (asymptotic freedom below ~1 GeV), while α1 and α2 decrease, so that they converge, but not exactly meet, at an energy of the order of 1015 GeV, which results to be the natural energy scale of GUTs, as it is displayed in the following Figure.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.